About radforsk

We focus on commercializing cancer research

Our goal is to develop better cancer treatment - for each individual patient. We invest in and develop both infrastructure through Radforsk Innovation and companies through Radforsk Invest, and connect businesses with cutting-edge research environments and entrepreneurs.

We are present in the entire value chain, from research in the academic institutions to start-up companies and into the commercial sphere. In this way, we gain unique knowledge and expertise to increase the value of a complex process at all stages. 

We are neither like other ecosystem builders nor investors, as we tend to say: "We don't think outside the box, for us there is no box".

Radforsk works to bring new cancer treatment from the laboratory to the market and to the patients who need it. One of the most important things we do is to identify and invest in promising technologies and companies that have the potential to improve patient care. At the same time, we work to ensure that companies and research environments have the best possible infrastructure and development conditions in order to succeed in a global industry.

Radforsk Invest's role goes far beyond traditional financing when we work to develop our portfolio companies. We are both investors, entrepreneurs and company developers. Ground-breaking new cancer treatment takes time to develop, and with our evergreen model we are long-term. We contribute strategically and operationally both before, during and after the establishment of companies. Radforsk Invest has a global approach to our investments.

Radforsk Innovation builds ecosystems and infrastructure that enable ground-breaking research and innovation. Radforsk Innovation is behind the national cancer cluster Oslo Cancer Cluster, the incubator Oslo Cancer Cluster Incubator, and not least the Oslo Cancer Cluster Innovation Park, which houses Ullern high school, units at Oslo University Hospital, the Cancer Registry and large and small private companies that develop cancer treatment.

The Oslo Cancer Cluster Innovation Park is an important part of Campus Radiumhospitalet, and is constantly expanding as more start-up companies are established and more international companies want to take part in the unique environment that has existed here at Montebello since the start in the 1930s. Read more about this in our story.

Radforsk has a very special position in the health industry in Norway, and we work politically consciously to help strengthen this important industry, alone and in collaboration with a wide range of actors.
Through our work, we want to contribute to a paradigm shift in cancer treatment by developing the most promising innovations and research initiatives.

We believe that through strategic investments and an irrepressible commitment, we can make a real difference to treating cancer better than today. Cancer is a disease that affects so many people - not only here in Norway, but all over the world. We are hugely motivated by the opportunity to improve the lives of cancer patients and their relatives.

    Team

  • Jónas Einarsson

    CEO Radforsk and Managing Director Radforsk Innovation

    je@radforsk.no +47 480 96 355
  • Anders Tuv

    Managing Director Radforsk Invest

    at@radforsk.no +47 982 06 826
  • Elisabeth Kirkeng Andersen

    Communications Manager and host for the Radium podcast

    eka@radforsk.no
  • Benedikte Johannesen

    Advisor

    bjo@radforsk.no
  • Bente Prestegård

    Project Manager

    bp@radforsk.no +47 41308175
  • Eirin Bragstad

    Finance Consultant

    eb@radforsk.no +47 41489648

    Board

  • Atle Brynestad

    Chair of the Board

  • Inger Sandlie

    Board Member

  • Ingar Pettersen

    Board Member

  • Bente-Lill Romøren

    Board Member

  • Erlend Bremertun Smeland

    Board Member

Our history

We have left our mark on history

Radforsk was established in 1987 as a technology transfer office for Radiumhospitalet under the name Radiumhospitalet's Research Foundation. Our mandate was then to handle the commercialization of the research at Radiumhospitalet, as well as the contractual and financial aspects of the clinical industrial studies at the hospital.

We had this role until 2007, when these functions were brought together at Oslo University Hospital. Under the leadership of Jónas Einarsson, who takes over as CEO in 2002, we are developing into the player we are today: An active investor who develops companies in close collaboration with researchers and an ecosystem builder. Einarsson thus joins the ranks of visionary leaders at Radiumhospitalet who have great ambitions on behalf of cancer patients, and take unconventional steps to realize them.

In the nearly 40 years we have existed, we have helped shape the development of Norwegian cancer research and development in a very special way. In this work, however, we stand on the shoulders of giants, where we have continued a proud tradition of thinking outside the box, because we do not believe in the concept of a box, in order to offer cancer patients better cancer treatment.

Our history is strongly linked to the history of the Radium Hospital, and not least the story of how zealots at the beginning of the 20th century ensured that Norwegian cancer patients received treatment with the newest cancer treatment available at the time, radium.

1903

Marie Curie and Ellen Gleditch

1913

Doctors Huitfeldt and Heyerdahl

1932

The Norwegian Radium Hospital

1948

Reidar Eker

1951

The Cancer Registry of Norway

1954

Hydro – the Institute for Cancer Research

1983

Jan Vincents Johannessen

1987

The Norwegian Radium Hospital's Research Foundation

1997

Algeta formed

2000

Photocure listed

2006

Oslo Cancer Cluster formed

2007

Nykode Therapeutics (formerly Vaccibody)

2009

'Window of hope' opened

2009

Collaboration between Oslo Cancer Cluster and Ullern Upper Secondary School

2014

Bayer acquires Algeta

2015

Prime Minister Erna Solberg opens Oslo Cancer Cluster Innovation Park

2020

The Nykode Agreement with Genentech

2023

The Ellen Gleditch Cyclotron in place

2023

ARTBIO, a new radiopharmaceutical adventure

2024

Completion of the new Radium Hospital

2025

Oslo Cancer Cluster Innovation Park, Block 4

2030

Oslo Science Hub opens

Resources

Press & media

svg

Radforsk Logo white

0mb

Download

jpg

Radforsk Logo black

0.74mb

Download

jpg

Press photo Jónas Einarsson

1.58mb

Download

jpg

Press photo Anders Tuv

0.74mb

Download

jpg

Press photo Anders & Jónas

1.02mb

Download

docx

About Radforsk, Norwegian

0.01mb

Download

docx

About Radforsk, English

0.01mb

Download

pdf

Rapport Åpenhetsloven 2023

0.18mb

Download

pdf

Rapport Åpenhetsloven 2024

0.21mb

Download